Events
-
-
-
ASCO 2026: Teclistamab extends survival, deepens remissions in relapsed multiple myeloma
-
ASCO 2026: Lancet Commission predict shortfall of 100 million cancer care workers by 2050
-
ASCO 2026: Phase 3 PEAK study could usher in new second-line therapy for GIST
-
ASCO 2026: Personalised vaccine boosts immune activity against brain cancer
-
ASCO 2026: GLP-1s may reduce metastatic progression of certain obesity-related cancers
-
ASCO 2026: Yoga may help cancer survivors sleep better and reduce anxiety, fatigue
-
-
Digital-first healthcare solutions to enhance patient experiences and outcomes
Greater uptake of digital-driven solutions in healthcare management could significantly improve patient experiences while saving…
New brain-permeable drug targets melanoma brain metastases
According to recent statistics, malignant melanoma is the leading cause of death from skin cancer…
Cancer cases and mortality in Africa predicted to double by 2040
Cancer cases and deaths are expected to double in Africa during the next two decades,…
SABCS 2022: Breast-conserving therapy may be a treatment option for some patients with multiple breast lesions
- EBCC 2022: Personalised breast cancer screening could improve cancer survival and reduce overdiagnosis
- EBCC 2022: Researchers find changes in blood proteins up to two years before breast cancer diagnosis
- EBCC 2022: Ultrasound-guided surgery is quicker, less painful and more effective for treating early form of breast cancer
More than 260 new drugs to treat cancer? Researchers look for “new cures in old drugs”
With more than 260 candidates identified, the range of non-cancer drugs with the potential to be used in new cancer…
JOIN THE ONCOLOGY NETWORK
If you would like even more free news articles, access to our exclusive HCP only content including the latest podcasts from The Oncology Podcast and our Industry Partner Podcasts (including links to all papers and show notes), along with all our other resources, head over to The Oncology Network and sign up - FREE forever for HCPs only.